Arlington Capital Partners' portfolio company, AVS Bio, has expanded its capabilities in antibody discovery and protein production through the acquisition of ImmunoPrecise Antibodies Europe from ImmunoPrecise Antibodies Ltd. This strategic move enhances AVS Bio's European presence, adding advanced services in antibody discovery, protein expression, and organoid growth factor development to its portfolio. With facilities in Utrecht and Oss, Netherlands, ImmunoPrecise Antibodies Europe provides comprehensive services to biotechnology and pharmaceutical companies, supporting the development of next-generation biologics. Post-acquisition, the company will continue to operate under its current management as a key European hub within the AVS Bio network, serving global pharmaceutical markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.